SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company’s Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr.

西雅图--（商业新闻短讯）--非侵入性医疗诊断技术的新兴开发商Know Labs，Inc.（纽约证券交易所美国代码：KNW）今天宣布任命四名新成员加入该公司的医疗和科学咨询委员会。该咨询委员会的新成员是杰夫·希区柯克、卡尔梅恩·库尔卡尼博士。

Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics..

Meng Tan和Satish Garg博士。他们为董事会带来了临床糖尿病管理方面的丰富经验，包括新技术的进步和医学诊断的创新。。

The Medical and Scientific Advisory Board is chaired by Know Labs’ Chief Medical Officer, Dr. James H. “Andy” Anderson. The Advisory Board provides guidance to the executive team and Board of Directors at Know Labs as the Company moves from the laboratory to clinical testing and thence to the FDA for clearance of the first truly non-invasive continuous glucose monitor..

医学和科学咨询委员会由Know Labs首席医学官James H.“Andy”Anderson博士担任主席。咨询委员会为Know Labs的执行团队和董事会提供指导，因为该公司从实验室转移到临床测试，然后再转移到FDA，以批准第一台真正的非侵入性连续血糖监测仪。。

Jeff Hitchcock is the Founder, President, and CEO of Children with Diabetes (CWD), an Honorary Member of the International Society for Pediatric and Adolescent Diabetes (ISPAD), and a recipient of the T1D Exchange 2021 Outstanding Parent Advisor Award. Hitchcock founded CWD in 1995 in response to his then seven-year-old daughter’s T1D diagnosis in 1989.

杰夫·希区柯克（Jeff Hitchcock）是糖尿病儿童（CWD）的创始人、总裁兼首席执行官，是国际儿科和青少年糖尿病学会（ISPAD）的荣誉成员，也是T1D Exchange 2021杰出父母顾问奖的获得者。希区柯克（Hitchcock）于1995年成立了CWD，以应对1989年他当时7岁的女儿的T1D诊断。

Inspired by his family’s experience, Hitchcock set out to create an informative online destination with resources and support for families dealing with T1D. CWD provides families and caregivers with guidance through original high-quality, science-based content and practical suggestions from trusted sources including pediatric endocrinologists, certified diabetes educators, nurses, nutritionists, researchers, advocates, and fellow parents..

受到家人经验的启发，希区柯克着手创建一个信息丰富的在线目的地，为处理T1D的家庭提供资源和支持。CWD通过原创的高质量、基于科学的内容和来自可靠来源的实用建议，为家庭和护理人员提供指导，这些来源包括儿科内分泌学家、认证糖尿病教育工作者、护士、营养学家、研究人员、倡导者和父母同伴。。

Karmeen Kulkarni, MS, RD, BC-ADM, CDCES, is a certified diabetes care and education specialist, board certified advanced diabetes manager and registered dietitian. Recognized internationally for her clinical expertise and contributions to nutrition and diabetes management, Kulkarni has received numerous national awards from the American Dietetic Association, American Diabetes Association and Abbott Diabetes Care.

Karmeen Kulkarni，MS，RD，BC-ADM，CDCES，是一名经过认证的糖尿病护理和教育专家，董事会认证的高级糖尿病经理和注册营养师。Kulkarni因其临床专业知识以及对营养和糖尿病管理的贡献而在国际上得到认可，她获得了美国饮食协会、美国糖尿病协会和雅培糖尿病护理协会的多项国家奖项。

Most recently, Kulkarni served as the Director of Global Scientific Affairs, Continuous Glucose Monitoring (CGM), at Abbott Diabetes Care. Prior to her time at Abbott Diabetes Care, Kulkarni coordinated the Diabetes Center at St. Mark’s Hospital, recognized as a Regional Center for the Intermountain West, serving adolescent to geriatric populations and specializing in insulin pumps, multiple daily injection (MDI) therapy, and CGMs..

最近，库尔卡尼在雅培糖尿病护理公司担任全球科学事务、连续血糖监测（CGM）主任。在参加雅培糖尿病护理之前，Kulkarni负责协调圣马克医院的糖尿病中心，该中心被公认为山间西部地区中心，为青少年和老年人群提供服务，并专门从事胰岛素泵，每日多次注射（MDI）治疗和CGM。。

Meng Tan, M.D., is currently Professor Emeritus of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes at the University of Michigan. Dr. Tan graduated with his M.D. from Dalhousie University, Halifax, Canada, and completed his post-doctoral training in diabetes at the Joslin Diabetes Center, Harvard University and in lipoprotein metabolism at the Cardiovascular Research Institute, University of California, San Francisco.

医学博士Meng Tan目前是密歇根大学代谢、内分泌和糖尿病系内科荣誉退休教授。Tan博士毕业于加拿大哈利法克斯的达尔豪西大学（Dalhousie University），拥有医学博士学位，并在哈佛大学乔斯林糖尿病中心（Joslin diabetes Center）完成了糖尿病博士后培训，并在加利福尼亚大学旧金山分校（University of California，San Francisco）心血管研究所完成了脂蛋白代谢博士后培训。

Prior to joining the University of Michigan, he was a Distinguished Medical Fellow, Lilly Research Laboratories and Global Medical Director, Diabetes Endocrine Platform Team at Eli Lilly and Company. Dr. Tan was Professor of Medicine and Biochemistry and Head, Division of Endocrinology and Metabolism, Dalhousie University before working in diabetes-related industry.

在加入密歇根大学之前，他是礼来研究实验室的杰出医学研究员，也是礼来公司糖尿病内分泌平台团队的全球医学总监。谭博士在从事糖尿病相关行业之前，曾任达尔豪西大学医学和生物化学教授，内分泌与代谢系主任。

He also previously held several leadership roles in diabetes-focused organizations, including serving as a past president of the Canadian Diabetes Association and Vice President of the International Diabetes Federation..

他还曾在以糖尿病为重点的组织中担任过多个领导职务，包括担任加拿大糖尿病协会前任主席和国际糖尿病联合会副主席。。

Satish Garg, M.D., is a Professor of Medicine and Pediatrics at the Adult Clinic of the Barbara Davis Center for Diabetes (BDC) at the University of Colorado School of Medicine. Dr. Garg joined the Barbara Davis Center in 1988 and became the Founder and Director of the BDC Adult Clinic. Dr. Garg has published over 350 original manuscripts in peer-reviewed journals and his research interests include the development of new diagnostic and therapeutic tools related to clinical diabetes management.

医学博士萨蒂什·加格（SatishGarg）是科罗拉多大学医学院芭芭拉·戴维斯糖尿病中心（BDC）成人诊所的医学和儿科教授。加格博士于1988年加入芭芭拉·戴维斯中心，成为BDC成人诊所的创始人和主任。加格博士在同行评审期刊上发表了350多篇原稿，他的研究兴趣包括开发与临床糖尿病管理相关的新诊断和治疗工具。

He has been part of several studies that have brought technological breakthroughs to diabetes care, including the FDA approved several Continuous Glucose Monitors (CGMs) and Medtronic MiniMed 670G and 780G hybrid closed-loop systems. Dr. Garg also serves as the Editor-in-Chief of Diabetes Technology and Therapeutics Journal, one of the leading journals in the field of emerging diabetes technologies and therapeutics.

他参与了多项为糖尿病护理带来技术突破的研究，包括FDA批准的几款连续血糖监测仪（CGMs）和美敦力Minimized 670G和780G混合闭环系统。加格博士还担任《糖尿病技术与治疗杂志》的主编，该杂志是新兴糖尿病技术和治疗领域的领先期刊之一。

He is also the Director of the Achieve Targets in Diabetes Care (ATDC) Conference held in July annually in Keystone, Colorado..

他还是每年7月在科罗拉多州Keystone举行的糖尿病护理实现目标（ATDC）会议的主任。。

The new appointees will join the two existing members of the Medical and Scientific Advisory Board, Larry Ellingson, Vice President of the National Diabetes Volunteer Leadership Council, who recently joined the Know Labs Board of Directors, and Donna Ryan, RN, RD, MPH, CDE, former President of the American Association of Diabetes Educators..

新任命的成员将加入医学和科学咨询委员会的两名现有成员，即最近加入Know Labs董事会的国家糖尿病志愿者领导委员会副主席拉里·埃林森和美国糖尿病教育者协会前主席唐娜·瑞安（Donna Ryan，RN，RD，MPH，CDE）。。

“We are very pleased to expand our existing Medical and Scientific Advisory Board with these distinguished researchers, innovators and clinical experts,” said Ron Erickson, CEO and Chairman at Know Labs. “They share a deep passion for advancing diabetes management, a central part of Know Labs’ mission.

Know Labs首席执行官兼主席罗恩·埃里克森（RonErickson）表示：“我们非常高兴能与这些杰出的研究人员、创新者和临床专家一起扩大现有的医学和科学咨询委员会。”。“他们对推进糖尿病管理有着浓厚的热情，这是Know Labs使命的核心部分。

As we work to bring the first FDA-cleared non-invasive blood glucose monitor to the marketplace, their insights will be instrumental in advancing our ongoing clinical research and in understanding the specific needs of the patient populations our device is designed to support.'.

当我们努力将第一台FDA批准的无创血糖监测仪推向市场时，他们的见解将有助于推进我们正在进行的临床研究，并有助于了解我们设备旨在支持的患者群体的具体需求。”。

For more information on Know Labs, visit www.knowlabs.co.

有关Know Labs的更多信息，请访问www.knowlabs.co。

About Know Labs, Inc.

关于Know Labs，Inc。

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors.

Know Labs，Inc.是一家上市公司，其股票在纽约证券交易所（NYSE American Exchange）以股票代码“KNW”进行交易。该公司的平台技术使用光谱学将电磁能引导穿过物质或材料以捕获独特的分子特征。该技术可以集成到各种可穿戴、移动或台式形状因素中。

This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor.

这种专利和正在申请专利的技术可以有效识别和监测以前只能通过侵入性和/或昂贵且耗时的实验室测试进行的分析物。该技术的第一个应用将是作为无创血糖监测仪销售的产品。

The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market..

该设备将为用户提供可访问且价格合理的血糖水平实时信息。该产品在上市前需要美国食品和药物管理局的批准。。

Safe Harbor Statement

安全港声明

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products.

本新闻稿包含的声明构成1995年《私人证券诉讼改革法案》、经修订的1933年《证券法》第27A节和经修订的1934年《证券交易法》第21E节所指的前瞻性声明。这些声明出现在本新闻稿的多个地方，包括所有不是关于Know Labs，Inc.，其董事或高管在以下方面的意图，信念或当前期望的历史事实声明：（i）融资计划；（ii）影响其财务状况或经营成果的趋势；（三）增长战略和经营战略；（iv）产品性能。

You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements.

您可以使用“可能”、“将”、“可能”、“应该”、“将”、“计划”、“预期”、“预期”、“继续”、“估计”、“项目”、“打算”、“可能”、“预测”、“可能”、“可能”、“潜在”等词语来识别这些陈述，其类似表达和变体旨在识别前瞻性陈述。

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

投资者应注意，任何此类前瞻性声明均不能保证未来业绩，并涉及风险和不确定性，其中许多风险和不确定性超出Know Labs，Inc.的控制能力，由于各种因素，实际结果可能与前瞻性声明中预测的结果存在重大差异。

These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2022, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time.

这些风险和不确定性还包括公司向美国证券交易委员会提交的文件中讨论的其他风险因素，包括截至2022年9月30日的10-K表年度报告、10-Q表和8-K表，以及我们不时向美国证券交易委员会提交的其他文件。

These documents are available on the SEC Filings sec.

这些文件可在美国证券交易委员会档案管理委员会获得。